Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
small molecules for diseases with significant unmet medical need, announced today the appointment of Michael D. Harvey , Ph.D. as Chief Development Officer. Dr. Harvey is a senior biotechnology executive with more than twenty years of experience in drug development, with expertise in a wide range of therapeutic areas including musculoskeletal rare diseases, obesity, oncology, and infectious diseases. Dr. Harvey also has strong abilities in strategic planning, execution, and alliance management, including pharma partner collaborations. Dr. Harvey joins Congruence from Inversago Pharma (acquired by Novo Nordisk in August 2023 ), where he led the development of several drug candidates for obesity, diabetes, and other serious metabolic diseases from discovery through Phase 2 studies. Prior to joining Inversago, he served as Vice President, Drug Development for rare diseases at Ipsen, following the acquisition of Clementia Pharmaceuticals Inc., which led to US FDA and Health Canada appro
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- 4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]Yahoo! Finance
- Succession drama grips Gucci as sales fail to make the cut [Yahoo! Finance]Yahoo! Finance
- Temedica Expands Its Advisory Board With Former Gematik CEO Markus Leyck Dieken [Yahoo! Finance]Yahoo! Finance
- Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/17/24 - Form 6-K
- 5/17/24 - Form SD
- 5/15/24 - Form 6-K
- NVO's page on the SEC website